When was Kiyatec founded?

Kiyatec was founded in 2005 and raised its 1st funding round 4 years after it was founded.

Where is Kiyatec located?

Kiyatec is headquartered in Pendleton, United States.

How many employees does Kiyatec have?

As of Jun 30, 2026, the latest employee count at Kiyatec is 14.

Is Kiyatec a funded company?

Kiyatec is a funded company, having raised a total of $29.5M across 13 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 27, 2009.

When was the latest funding round of Kiyatec?

Kiyatec's latest funding was a $***** Series C round on Nov 13, 2025, with participation from 0 investor.

Where does Kiyatec rank among its competitors?

Kiyatec ranks 38th amongst 698 active competitors, of which 199 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Bit.bio, which secured $50M in Jan, 2026.

Who are the top competitors of Kiyatec?

Kiyatec's top competitors include Guardant Health, Natera and Myriad Genetics. Among them, Bit.bio secured the most recent funding round in January, 2026.

Kiyatec - 2026 Company Profile, Team, Funding & Competitors

Kiyatec is a series C company based in Pendleton (United States), founded in 2005. It operates as a Develops 3D phenotypic cell-based assays and diagnostic solutions for prediction of patients’ response to cancer drug treatment. Kiyatec has raised $29.5M in funding from investors like VentureSouth, Bruker and SCRA. The company has 698 active competitors, including 199 funded and 140 that have exited. Its top competitors include companies like Guardant Health, Natera and Myriad Genetics.

Company Details

Kiyatec specializes in developing solutions for the prediction of patient's response to cancer drug treatment, with a focus on data correlation to human clinical outcomes. It develops live phenotypic 3D cell-based models for drug response profiling and applies them to generate information relevant to preclinical testing, clinical trials, and clinical diagnostics applications. This information helps in drug selection, minimizing clinical trials failures, and maximizing patient outcomes in the clinic.

Website: kiyatec.com
Social

Key Metrics

Founded Year

2005

Location

Pendleton, United States

Stage

Series C

Total Funding

$29.5M in 13 rounds

Latest Funding Round

Series C, Nov 13, 2025, $*****

Investors

VentureSouth & 14 more

Ranked

38^th among 698 active competitors

Employee Count

14 as on Jun 30, 2026

Similar Companies

Guardant Health & 893 more

View Kiyatec's full profile

Kiyatec is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Kiyatec Inc. CIN: 1547577 , United States, Active		$1M - $5M (As on Nov 27, 2017)	-	-

Kiyatec has raised a total funding of $29.5M over 13 rounds. Its first funding round was on Feb 27, 2009. Kiyatec has 15 institutional investors.

Here is the list of recent funding rounds of Kiyatec:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 13, 2025	6686087	Series C	9915754	9786073	7679109	5659864
Oct 22, 2024	1138274	Series C	9677080	4391077	4127874	3521076
May 18, 2023	9033748	Series C	5830266	5545205	3652672	Brain Tumor Investment Fund & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Kiyatec's funding rounds and investors

Kiyatec's Board of Directors

Kiyatec's board has 18 active members. Jason Robart, Bruce Nash, Bob Silverman, Eric Perreault, Christopher Brotherton, David E. Orr, Christine Dixon Thiesing, David E Orr, Gregory Zaic, Robert J. Silverman, Martin Ettlemyer, Scott Isacksen, Melissa Rayner, Christine Dixon Thiesing, Robert Silverman, H. Lee Higdon III, Matthew R. Gevaert and Matthew Gevaert are independent board members.

Here is the list of Kiyatec's board of directors:

Name	Type	Representing	Status	Duration
Jason Robart	Independent board member	-	Current	3y 6m
pimnhdr	Independent board member	-	Current	4y 5m
yfjpy{e	Independent board member	-	Current	3y 8m
y{iythn	Independent board member	-	Current	3y 7m
lqyhiku	Independent board member	-	Current	1y 9m
xyiorsp	Independent board member	-	Current	5y 2m
fxesfng	Independent board member	-	Current	9y 6m
fjapykf	Independent board member	-	Current	5y 5m
cljsyka	Independent board member	-	Current	6y 6m
wzukbas	Independent board member	-	Current	2y 9m
mxkafpi	Independent board member	-	Current	2y 5m
avlw{jw	Independent board member	-	Current	1y 8m
fwyepxw	Independent board member	-	Current	8y 4m
vzqzj{f	Independent board member	-	Current	4y 4m
xlcvhji	Independent board member	-	Current	6y 4m
aijhdje	Independent board member	-	Current	3y 2m
rujklql	Independent board member	-	Current	1y 8m
v{gjfls	Independent board member	-	Current	3y 4m

Kiyatec's employee count trend

Kiyatec has 14 employees as of Jun 26. Here is Kiyatec's employee count trend over the years:

Uncover Kiyatec's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kiyatec include Guardant Health, Natera and Myriad Genetics. Here is the list of Top 10 competitors of Kiyatec, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	Khosla Ventures, Orbimed & 25 others	79/100
2nd	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Foresite Capital & 17 others	77/100
3rd	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	72/100
4th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Deerfield, Casdin Capital & 11 others	71/100
5th	Exact Sciences 1995, Madison (United States), Acquired	Provider of non-invasive molecular diagnostic testing solutions for cancer	-	Petrillo Capital, Back Bay Group & 8 others	71/100
6th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Braidwell & 19 others	70/100
7th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Beyond Ventures, Ping An Ventures & 21 others	70/100
8th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
9th	Bit.bio 2016, Cambridge (United Kingdom), Series C	Manufacturer of programmed human cells for research and drug discovery	$266M	M&G, Foresite Capital & 53 others	68/100
10th	Delfi Diagnostics 2019, Baltimore (United States), Series B	Provider of DNA sequencing for cancer detection	$332M	Merck Global Health Innovation Fund, DFJ Growth ... & 19 others	68/100
38th	Kiyatec 2005, Pendleton (United States), Series C	Develops 3D phenotypic cell-based assays and diagnostic solutions for prediction of patients’ response to cancer drug treatment	$29.5M	NMT Capital, AIM Group & 13 others	55/100